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Increase in Circulating Endothelial Progenitor
Cells by Statin Therapy in Patients With Stable
Coronary Artery Disease
Mariuca Vasa, MD; Stephan Fichtlscherer, MD; Klaudia Adler; Alexandra Aicher, MD;
Hans Martin, MD; Andreas M. Zeiher, MD; Stefanie Dimmeler, PhD
Background—Therapeutic neovascularization may constitute an important strategy to salvage tissue from critical
ischemia. Circulating bone marrow–derived endothelial progenitor cells (EPCs) were shown to augment the
neovascularization of ischemic tissue. In addition to lipid-lowering activity, hydroxymethyl glutaryl coenzyme A
reductase inhibitors (statins) reportedly promote the neovascularization of ischemic tissue in normocholesterolemic
animals.
Methods and Results—Fifteen patients with angiographically documented stable coronary artery disease (CAD) were
prospectively treated with 40 mg of atorvastatin per day for 4 weeks. Before and weekly after the initiation of statin
therapy, EPCs were isolated from peripheral blood and counted. In addition, the number of hematopoietic precursor cells
positive for CD34, CD133, and CD34/kinase insert domain receptor was analyzed. Statin treatment of patients with
stable CAD was associated with an ’1.5-fold increase in the number of circulating EPCs by 1 week after initiation of
treatment; this was followed by sustained increased levels to ’3-fold throughout the 4-week study period. Moreover,
the number of CD34/kinase insert domain receptor–positive hematopoietic progenitor cells was significantly augmented
after 4 weeks of therapy. Atorvastatin treatment increased the further functional activity of EPCs, as assessed by their
migratory capacity.
Conclusion—The results of the present study define a novel mechanism of action of statin treatment in patients with stable
CAD: the augmentation of circulating EPCs with enhanced functional activity. Given the well-established role of EPCs
of participating in repair after ischemic injury, stimulation of EPCs by statins may contribute to the clinical benefit of
statin therapy in patients with CAD. (Circulation. 2001;103:2885-2890.)
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Blood cholesterol lowering with statins is well establishedas a long-term strategy to reduce death and ischemic
cardiovascular events in patients with stable coronary artery
disease (CAD).1–3 Major mechanisms by which lipid lower-
ing is thought to improve outcome include preventing the
development of new atherosclerotic lesions and stabilizing
existing atherosclerotic plaques.4 In addition, statins can
reduce vascular inflammation,5 decrease platelet aggregabil-
ity and thrombus deposition,6 and increase endothelium-
derived nitric oxide production.7 Most recently, statins have
been reported to promote the neovascularization of ischemic
tissue in normocholesterolemic animals.8
Therapeutic neovascularization may constitute an important
way to salvage tissue from critical ischemia.9 Neovasculariza-
tion in the adult is thought to result exclusively from the
migration and proliferation of preexisting, fully differentiated
endothelial cells (a process referred to as angiogenesis).10 Recent
studies, however, demonstrated that circulating bone marrow–
derived endothelial progenitor cells (EPCs) home to sites of
neovascularization and differentiate into endothelial cells in
situ11,12 in a manner consistent with a process termed vasculo-
genesis.13 Importantly, mobilization of bone marrow-derived
EPCs augments the neovascularization of ischemic tissue,14 thus
suggesting that the mobilization of EPCs might represent a
useful strategy for clinical therapy of ischemic heart disease.
Therefore, we tested the hypothesis that statin therapy
might augment circulating EPCs in patients with stable CAD.
Methods
Characteristics of Study Patients and
Healthy Controls
Fifteen patients with angiographically documented CAD were pro-
spectively studied. The patient characteristics are summarized in
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Table 1. Patients with concomitant inflammatory or malignant
disease were excluded and, to avoid any potentially confounding
effect of myocardial ischemia on EPC kinetics, none of the patients
had flow-limiting coronary artery stenosis (.50% diameter reduc-
tion) at the time of inclusion into the study. In addition, patients with
unstable angina or myocardial infarction within the preceding 3
months were excluded. None of the patients had previously been
treated with a statin. The LDL cholesterol serum levels ranged from
57 to 207 mg/dL at the time of inclusion into the study.
The age-matched healthy control group (n59) consisted of 3
women and 6 men with a mean age of 6065.3 years without any
evidence of CAD by history and physical examination. In an
additional 5 healthy volunteers (mean age 3666.3 years), EPC
kinetics were investigated 3 times over a 4-week period to assess any
potential spontaneously occurring changes in EPC numbers.
Study Protocol
The 15 study patients received 40 mg of atorvastatin (Pfizer) per day
over 4 weeks. Before and weekly after the initiation of statin therapy,
40 mL of venous blood was collected to measure circulating EPCs,
serum cholesterol levels, and vascular endothelial growth factor
(VEGF), tumor necrosis factor-a (TNF-a), and granulocyte macro-
phage colony-stimulating factor (GM-CSF) serum levels. Informed
consent was obtained from all patients and healthy volunteers, and
the study protocol was approved by the local Ethics Committee of
the University of Frankfurt.
EPC Culture Assay
Mononuclear cells were isolated by density-gradient centrifugation
with Biocoll from 20 mL of peripheral blood. Immediately after
isolation, 43106 mononuclear cells were plated on 24-well culture
dishes coated with human fibronectin and gelatin (Sigma) and
maintained in endothelial basal medium (EBM, CellSystems) sup-
plemented with EGM SingleQuots and 20% FCS. After 4 days in
culture, nonadherent cells were removed by a thorough washing with
PBS, and adherent cells underwent cytochemical analysis.
Characterization of EPCs
To detect the uptake of 1,19–dioctadecyl–3,3,39,39–tetramethylin-
docarbocyanine–labeled acetylated low-density lipoprotein
(DiLDL), cells were incubated with DiLDL (2.4 mg/mL) at 37°C for
1 hour. Cells were then fixed with 2% paraformaldehyde for 10
minutes, and lectin staining was performed by incubation with
fluorescein isothiocyanate (FITC)–labeled Ulex europaeus aggluti-
nin I (lectin, 10 mg/mL; Sigma) for 1 hour. After the staining,
samples were viewed with an inverted fluorescent microscope
(Zeiss). Dual-stained cells positive for both lectin and DiLDL were
judged to be EPCs, and they were counted per well. Two to three
independent investigators evaluated the number of EPCs per well by
counting 3 randomly selected high-power fields.15
To detect the expression of endothelial marker proteins, EPCs
were detached with 1 mmol/L EDTA in PBS, followed by repeated
gentle flushing through a pipette tip. Cells were incubated for 15
minutes with phycoerythrin-labeled monoclonal antibodies against
human kinase insert domain receptor (KDR) (Sigma) and human
vascular endothelium–cadherin and a FITC–labeled monoclonal
antibody against von Willebrand factor. After treatment, the cells
were lysed and fixed in 4% paraformaldehyde. CD14-positive
monocytes were obtained by positive selection with CD14 immuno-
magnetic microbeads (Milteny, Biotech) using an auto–magnetic cell
sorting cell separation device. Single and 2-color flow cytometric
analysis were performed using a fluorescence-activated cell sorter
(FACS) SCAN flow cytometer (Becton Dickinson).
Flow Cytometry Analysis
A volume of 100 mL of peripheral blood was incubated for 15
minutes in the dark with monoclonal antibodies against human KDR
(Sigma), the FITC-labeled monoclonal antibody against human
CD45 (Becton Dickinson), the phycoerythrin-conjugated monoclo-
nal antibody against human CD133 (Milteny), and the FITC- or
phycoerythrin-conjugated monoclonal antibody against human
CD34 (Becton Dickinson). Isotype-identical antibodies served as
controls (IgG1-phycoerythrin and IgG2a-FITC, Becton Dickinson).
Each analysis included 60 000 events.
Migration Assay
Isolated EPCs were detached using 1 mmol/L EDTA in PBS (pH
7.4), harvested by centrifugation, resuspended in 500 mL of EBM,
counted, and placed in the upper chamber of a modified Boyden
chamber. The chamber was placed in a 24-well culture dish contain-
ing EBM and human recombinant VEGF (50 ng/mL). After 24 hours
of incubation at 37°C, the lower side of the filter was washed with
PBS and fixed with 2% paraformaldehyde. For quantification, cell
nuclei were stained with 49,6-diamidino-phenylidole. Migrating cells
into the lower chamber were counted manually in 3 random
microscopic fields.16
Serum VEGF, GM-CSF, and TNF levels
Serum levels of the cytokines were measured by a high-sensitive
ELISA assay (R&D Systems) according to the manufacturer’s
instructions. Samples were checked by serial dilution, and measure-
ments were performed at least in duplicate.
Statistical Analysis
Data are expressed as mean6SEM. Continuous variables were tested
for normal distribution with the Kolmogorov-Smirnov test and
compared by 1-way ANOVA. Categorical variables were compared
using the x2 test and the Fisher exact test. In the case of non-normal
distribution, nonparametric tests were used (Mann-Whitney U test or
Kruskal-Wallis ANOVA on ranks). Differences in EPC number and
FACS parameters were examined by repeated-measures ANOVA.
Linear regression analysis and nonparametric bivariate correlation
(Spearman rank correlation coefficient) were used to compare
increases in EPCs versus a reduction of LDL cholesterol levels.
TABLE 1. Baseline Clinical Characteristics of the Patients
Age, y 64.362.6
Men, n (%) 12 (80)
No of diseased coronary arteries, n (%)
1 9 (60)
2 2 (13.3)
3 4 (26.7)
Mecial history, n (%)
Hypertension 11 (73.3)
Diabetes mellitus 5 (33.3)
Current smoking 3 (20)
Family history of CAD 3 (20)
Left ventricular ejection fraction 58.362.2
Current medication, n (%)
Aspirin 11 (73.3)
Cumarines 3 (20)
b-Blocker 12 (80)
ACE inhibitors 11 (73.3)
Insulin 3 (20)
Lipid profile, mg/dL
Total cholesterol 213612.2
LDL cholesterol 145611.5
HDL cholesterol 43.562.3
Triglycerides 131617.4
Data are expressed as mean6SE or n (%). n515.
2886 Circulation June 19, 2001
 by on June 24, 2010 circ.ahajournals.orgDownloaded from 
Statistical significance was assumed if a null hypothesis could be
rejected at P,0.05. All statistical analyses were performed with
SPSS for Windows 7.0.
Results
Effect of Atorvastatin on EPCs
EPCs were isolated and cultivated from peripheral blood and
characterized as dual-stained cells positive for DiLDL and
lectin. In addition, the endothelial phenotype was confirmed
by demonstrating the expression of the endothelial marker
proteins KDR, vascular endothelium–cadherin and von Wil-
lebrand factor by flow cytometry (Figure 1A). Moreover,
EPCs were double-positive for DiLDL uptake and von
Willebrand factor expression (Figure 1B). To exclude the
possibility that these cells could be monocytes, the same
staining procedure was repeated with isolated CD14-positive
monocytes. As expected, monocytes were positive for DiLDL
uptake but negative for von Willebrand factor expression
(Figure 1B).
Before initiating statin therapy, the number of EPCs was
lower but not significantly reduced in patients with CAD
(190649 EPCs/mm2) compared with age-matched healthy
controls (310655 EPCs/mm2, P50.052). Treatment with 40
mg of atorvastatin per day was associated with a significant
increase in the number of circulating EPC in patients with
CAD (Figure 2, P,0.05 for trend). As illustrated in Figure
2A, a significant (P50.016), ’1.5-fold increase in EPCs was
observed after only 1 week of treatment; this was followed by
a further increase to 3-fold at week 2 and was sustained at
.4-fold throughout the 4-week study period. In addition,
atorvastatin treatment also augmented EPC numbers in 3
healthy volunteers (3 men aged 50611 years) from 318668
to 494668 and 6776101 EPCs/mm2 after 1 and 3 weeks,
respectively (P,0.05). In contrast, repeated measurements of
circulating EPCs in 5 healthy control subjects without statin
treatment over a 4-week period revealed essentially identical
values (331646, 305629, and 287650 EPCs/mm2 at base-
line, 2 weeks, and 4 weeks, respectively). Thus, statin
treatment significantly augments the number of circulating
EPC within 1 week of treatment.
Effect of Atorvastatin on Hematopoietic
Progenitor Cells
EPCs are thought to derive from CD34-positive hematopoi-
etic progenitor cells.11,17–19 The subset of endothelial precur-
sor cells is characterized by the coexpression of endothelial
Figure 1. EPC characteristics. A, The expression of KDR recep-
tor, von Willebrand factor (vWF), and vascular endothelium (VE)-
cadherin in EPCs was analyzed by FACS and compared with
isotype controls. B, EPCs (left) were compared with CD14-
positive isolated monocytes (right). DiLDL uptake and von Wille-
brand factor staining were determined by FACS. Quadrants
were set on the basis of FITC isotype controls and cells without
DiLDL incubation. Representative images from 3 to 20 experi-
ments are shown.
Figure 2. A, Atorvastatin therapy augments EPCs. EPCs were
isolated before and after patients with stable CAD were treated
with atorvastatin (40 mg/d). EPCs were characterized as adher-
ent cells with double-positive staining for DiLDL and lectin.
*P,0.05 vs day 0. Representative images are shown in B.
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marker proteins such as VEGF receptor 2 (KDR).17–19 The
baseline number of circulating CD34/KDR-positive cells was
reduced in patients with CAD compared with healthy age-
matched volunteers (0.017360.004% versus 0.02960.006%
in healthy controls, P50.116).
Treatment with atorvastatin led to a increase in CD34/
KDR-positive cells starting 7 days after initiating treatment
(Figure 3). In contrast, the overall number of circulating
CD34-positve cells did not change during the treatment
period (0.06760.01% at baseline versus 0.07660.013% after
4 weeks, P5NS). Likewise, the number of CD133-positive
hematopoietic progenitor cells, which represent a more im-
mature subset of CD34-positive cells, remained unchanged
(0.0760.012% versus 0.0560.009% after 4 weeks, P5NS).
Finally, atorvastatin treatment did not affect the total number
of mononuclear cells (0.8260.083106 cells/mL versus
0.8560.093106 cells/mL after 4 weeks, P5NS). Again, in
healthy control subjects without statin treatment, all param-
eters tested remained constant during the observation period,
whereas statin treatment in 3 healthy volunteers significantly
increased the number of CD34/KDR-positive cells to 365%
after 3 weeks of treatment (P50.028). Thus, a 4-week period
of statin treatment seems to stimulate the differentiation of
CD34-positive cells into EPCs rather than to augment the
numbers of circulating hematopoietic progenitor cells.
Effects of Atorvastatin on the Migratory Capacity
of Isolated EPCs
To assess the potential functional effects of statin therapy on
EPCs, we analyzed the migratory capacity of isolated EPCs in
response to VEGF in a subset of 12 patients before and after
3 and 4 weeks of treatment with 40 mg of atorvastatin per
day. At baseline, patients with stable CAD had lower num-
bers of migrating EPCs than healthy volunteers (1165.8
versus 31.964.8 migrating EPCs per high-power field, re-
spectively, P,0.05). As illustrated in Figure 4, atorvastatin
treatment significantly augmented the migration of isolated
EPCs from 11.565.9 to 34.6613.5 migrating EPCs/high
power field after 3 weeks (P50.009). Thus, statin therapy
increases the number of circulating EPCs and stimulates the
functional activity of these cells.
Effects of Atorvastatin on Serum Cholesterol and
Cytokine Levels
Treatment with 40 mg of atorvastatin per day resulted in a
decrease in LDL serum cholesterol levels (Figure 5). However,
neither the absolute number of EPCs at baseline nor the EPC
kinetics during treatment correlated with LDL cholesterol levels
(r50.377, P50.165) or statin-induced changes in LDL choles-
terol serum levels (r520.017, P50.955; r50.134, P50.694;
and r520.199, P5496 at 1, 2, and 3 weeks, respectively). In
addition, statin treatment did not affect serum levels of VEGF,
GM-CSF, or TNF-a (Table 2), which all modulate EPC mobi-
lization or angiogenesis in vivo.14,20,21
Discussion
The results of the present study demonstrate that statin
therapy is associated with an increase in the number of
circulating EPCs in patients with stable CAD. The increase in
Figure 3. Atorvastatin therapy increases CD34/KDR-positive
hematopoietic stem cells. CD34/KDR-positive lymphocytes were
analyzed in peripheral blood from patients with stable CAD
before and weekly after atorvastatin therapy, as indicated.
*P,0.05 vs day 0. Data are mean6SEM.
Figure 4. Migratory capacity of EPCs after statin therapy.
Migration of EPCs was analyzed in a subset of 12 patients by
using a modified Boyden chamber, as outlined in Methods. Data
are mean6SEM.
Figure 5. Effects of statin therapy on LDL cholesterol serum lev-
els. LDL cholesterol levels were measured before and after ator-
vastatin therapy. *P,0.05 vs day 0.
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EPCs was statistically significant as early as 1 week after the
initiation of atorvastatin treatment, and it plateaued at a 3-fold
increase at 3 to 4 weeks of therapy. The increased number of
EPCs was paralleled by an enhancement of the migratory
capacity of isolated EPCs. Mobilization of circulating EPCs
with enhanced functional activity might contribute to the
well-established beneficial effects of statins in patients with
CAD.
Although the proportional contribution of angiogenesis and
vasculogenesis to the neovascularization of adult tissue re-
mains to be determined, it is well established that EPCs
participate in repair after ischemic injury. Experimental
hindlimb ischemia in mice increases the number of circulat-
ing EPCs by .400%.14 The angiogenic growth factor VEGF,
which is upregulated in the ischemic myocardium of patients
with myocardial infarction,22 has been shown to mobilize
EPCs in both mice and men.16,20 Finally and most impor-
tantly, transplantation of blood-derived EPCs significantly
augmented ischemia-induced neovascularization of the hind-
limb23,24 and promoted limb salvage in nude mice.15 Thus, the
finding that statin therapy augments the number of circulating
EPCs in patients with CAD implies that vasculogenesis may
contribute to statin-mediated repair after ischemic injury,
which was very recently demonstrated for the rabbit model of
hindlimb ischemia.8
Upregulation of angiogenic growth factors constitutes a
fundamental survival response to tissue ischemia. Therefore,
VEGF seems to be a key regulatory cytokine orchestrating
endogenous neovascularization by modulating endothelial
cell migration and proliferation and circulating cellular ele-
ments.9 Recent experimental and clinical studies have dem-
onstrated that VEGF affects endothelial cell migration and
proliferation and significantly alters the kinetics of EPCs.11,20
Treating mice with recombinant human VEGF165 increases
the number of EPCs by 245% and 214% after 1 and 4 days,
respectively.16 Likewise, in patients with critical limb ische-
mia receiving VEGF gene transfer, the number of EPCs
increased by 154% and 153% at days 14 and 28 after
treatment, respectively, in parallel with an ’2-fold increase
in VEGF plasma levels.20 In the present study using a culture
assay identical to one used previously to quantify circulating
EPC kinetics, a .3-fold increase in circulating EPCs was
observed 2 weeks after initiating atorvastatin treatment in
patients with stable CAD. Thus, the effects of statin therapy
in augmenting circulating EPCs seem to be at least compa-
rable to the effects of exogenous VEGF administration.
The mechanisms mediating the effects of statins on EPC
kinetics in humans remain to be determined. Our data suggest
that the modulation of EPC kinetics after statin treatment is
unrelated to the decrease in serum LDL cholesterol levels. In
a manner similar to the mobilization of hematopoietic pro-
genitor cells,25 cytokines like GM-CSF have also been shown
to exert potent stimulatory effects on EPC kinetics.14 How-
ever, in the present study, atorvastatin did not affect the serum
levels of GM-CSF or TNF-a in patients with CAD. Likewise,
VEGF serum levels did not significantly change during
atorvastatin treatment. It is known that statins can regulate a
variety of intracellular signaling pathways, including Rho
GTPase, thereby stabilizing endothelial nitric oxide synthase
(eNOS) mRNA levels.7 Moreover, statins were recently
shown to stimulate the protein kinase Akt,8 which activates
the enzymatic activity of eNOS,26,27 mediates VEGF-induced
endothelial cell migration,28,29 and thereby plays an important
role in mature endothelial cells.30 Thus, one may speculate
that statin-induced stimulation of the Akt/eNOS pathway
might contribute to the observed effects of statins on the
functional improvement of EPCs.
Obviously, because of the limitations imposed by studying
patients, we cannot determine the molecular pathway(s)
responsible for statin-induced augmentation in circulating
EPCs in our patients with stable CAD. Moreover, because of
the potent beneficial effect of statins in normocholesterolemic
patients with CAD, a placebo control group cannot be
provided for ethical reasons. However, the finding that statin
therapy also increases EPC levels in healthy volunteers,
whereas EPC levels remained unchanged in the untreated
healthy control group, supports the hypothesis that statins
directly affect EPC levels.
Interestingly, patients with CAD revealed reduced EPC
numbers and migration. Although the data did not reach
statistical significance with respect to EPC levels, one may
speculate that individual risk factors contribute to the impair-
ment of EPC numbers and function. Further studies with
larger patient numbers are required to elucidate the potential
contribution of specific risk factors for CAD on EPC number
and function.
In conclusion, the results of the present study define a
novel mechanism of action of statin treatment in patients with
stable CAD: namely, the augmentation of circulating EPCs
with enhanced functional activity. Our data further suggest
that statin treatment seems to stimulate the differentiation of
a subset of endothelial precursor cells into EPCs rather than
augmenting the number of circulating hematopoietic stem
cells. Given the well-established role of EPCs participating in
repair after ischemic injury, the mobilization of EPCs by
statins may contribute to the clinical benefit of statin therapy
in patients with CAD, in addition to the effects of statins on
serum cholesterol levels and atherosclerotic plaque stabiliza-
tion. The potential of statins to improve the neovasculariza-
tion of ischemic tissue suggests that statin therapy may
support one of the most fundamental survival responses to
maintain tissue viability in the face of acute or chronic
myocardial ischemia in patients with obstructive CAD. In
fact, statin therapy was recently shown to rapidly enhance
coronary blood flow in patients with stable CAD31 and to
reduce myocardial ischemia after an acute ischemic episode
within a few weeks of treatment.32
TABLE 2. Initial and Follow-Up Serum Cytokine Levels in
Patients With Stable CAD Undergoing Atorvastatin Treatment
Variable Day 0 Day 14 Day 28
VEGF, pg/mL 67.7616.7 38.967.3 63.7616.1
GM-CSF, pg/mL 0.2360.05 0.2660.05 0.1760.05
TNF-a, pg/mL 1.760.3 1.760.3 1.560.2
Data are expressed as mean6SE.
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